

1 **MET receptor activation by stromal cells serves as promising target**  
2 **in melanoma brain metastases**

3  
4 **Torben Redmer<sup>1,2,\*</sup>, Elisa Schumann<sup>3,4</sup>, Kristin Peters<sup>5</sup>, Martin E. Weidemeier<sup>6</sup>, Stephan**  
5 **Nowak<sup>6</sup>, Henry W.S. Schroeder<sup>6</sup>, Anna Vidal<sup>1</sup>, Helena Radbruch<sup>3</sup>, Annika Lehmann<sup>7</sup>,**  
6 **Susanne Kreuzer-Redmer<sup>8</sup>, Karsten Jürchott<sup>9</sup>, Josefine Radke<sup>5,\*</sup>**

7  
8 \*corresponding authors

9 Torben Redmer

10 Email: [torben.redmer@vetmeduni.ac.at](mailto:torben.redmer@vetmeduni.ac.at)

11 Josefine Radke

12 Email: [josefine.radke@med.uni-greifswald.de](mailto:josefine.radke@med.uni-greifswald.de)

13  
14 <sup>1</sup>Institute for Medical Biochemistry, University of Veterinary Medicine Vienna, Vienna, Austria

15 <sup>2</sup>Institute of Pathology, Unit of Laboratory Animal Pathology, University of Veterinary  
16 Medicine Vienna, Veterinärplatz 1, Vienna, Austria

17 <sup>3</sup>Department of Neuropathology, Charité-Universitätsmedizin Berlin, corporate member of  
18 Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin,  
19 Germany

20 <sup>4</sup>German Cancer Consortium (DKTK), Partner Site Berlin, CCCC (Campus Mitte), Berlin,  
21 Germany

22 <sup>5</sup>Institute of Pathology, University Medicine Greifswald, Greifswald, Germany

23 <sup>6</sup>Department of Neurosurgery, University Medicine Greifswald, Greifswald, Germany

24 <sup>7</sup>Institute of Pathology, Charité-Universitätsmedizin Berlin, corporate member of Freie  
25 Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin,  
26 Germany

27 <sup>8</sup>Nutrigenomics Unit, Institute of Animal Nutrition and Functional Plant Compounds,  
28 University of Veterinary Medicine Vienna, Vienna, Austria

29 <sup>9</sup>Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Center for Regenerative  
30 Therapies (BCRT), Berlin, Germany.

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54 **Abstract**

55 The development of brain metastases hallmarks disease progression in 20-40% of  
56 melanoma patients and is a serious obstacle to therapy. Understanding the processes  
57 involved in the development and maintenance of melanoma brain metastases (MBM) is  
58 critical for the discovery of novel therapeutic strategies. Here, we generated transcriptome  
59 and methylome profiles of MBM showing high or low abundance of infiltrated Iba1<sup>high</sup> tumor-  
60 associated microglia and macrophages (TAMs). Our survey identified potential prognostic  
61 markers of favorable disease course and response to immune checkpoint inhibitor (ICI)  
62 therapy, among them *APBB1IP* and the interferon-responsive gene *ITGB7*. In MBM with high  
63 *ITGB7/APBB1IP* levels, the accumulation of TAMs correlated significantly with the immune  
64 score. Signature-based deconvolution of MBM via single sample GSEA revealed enrichment  
65 of interferon-response and immune signatures and revealed inflammation, stress and MET  
66 receptor signaling. MET receptor phosphorylation/activation maybe elicited by inflammatory  
67 processes in brain metastatic melanoma cells via stroma cell-released HGF. We observed  
68 phospho-MET<sup>Y1234/1235</sup> in a subset of MBM and observed marked response of brain  
69 metastasis-derived cell lines (BMCs) that lacked druggable BRAF mutations or developed  
70 resistance to BRAF inhibitors (BRAFi) *in vivo* to MET inhibitors PHA-665752 and ARQ197  
71 (tivantinib). In summary, the activation of MET receptor in brain colonizing melanoma cells by  
72 stromal cell-released HGF may promote tumor cells self-maintenance and expansion might  
73 counteract ICI therapy. Therefore, therapeutic targeting of MET possibly serves as promising  
74 strategy to control intracranial progressive disease and improve patient survival.

75 **Key words:** Melanoma, brain metastasis, TAMs, interferon signaling, MET receptor

76

77

78

79

## 80 **Introduction**

81 The interaction of brain colonizing tumor cells with the tumor microenvironment (TME),  
82 mainly comprising innate and adaptive immune cells, microglia, astrocytes, neurons and  
83 oligodendrocytes crucially determines the developmental stages of brain metastases (BM).  
84 Brain metastases are observed in 20 – 40% of melanoma patients during the course of  
85 disease and micrometastases are evident in more than 75% of autopsied brains<sup>1</sup>. Hence,  
86 only a subset of melanoma cells that entered the brain develop symptomatic and detectable  
87 BM during the lifetime of melanoma patients. Unlike peripheral metastases, the emergence  
88 of BM depends on a plethora of environmental cues such as the spatiotemporal availability of  
89 factors that are provided by cells of the TME, supporting or repressing tumor cell growth<sup>2</sup>.  
90 Moreover, single-cell RNA sequencing (scRNAseq) studies have confirmed regional  
91 heterogeneity of astrocytes<sup>3</sup>, oligodendrocytes<sup>4</sup> and microglia<sup>5,6</sup> in healthy human brains.  
92 Particularly, astrocytes and microglia adopt a reactive cell state<sup>7,8</sup> that accompanies  
93 secretion of pro- and anti-inflammatory factors under pathological conditions<sup>9,10</sup>. It is  
94 therefore possible that subfractions of astrocytes and microglia communicate and react with  
95 tumor cells in different ways. Probably, neuroinflammation precedes colonization of the brain  
96 by tumor cells. However, tumor cells invading the brain amplify inflammatory processes  
97 mediated by astrocytes and infiltrating tumor-associated microglia and macrophages  
98 (TAMs)<sup>11,12</sup>. Recently, signaling mediated by hepatocyte growth factor (HGF) and the related  
99 receptor MET (c-MET, HGFR) was identified as the trigger of reactive microglia<sup>13</sup>. HGF is  
100 thereby secreted by microglia in the context of trauma but also under normal conditions and  
101 seems to play a special role in the growth and self-renewal of neural stem cells in the  
102 subventricular zone (SVZ) of rat brains<sup>14,15</sup>. Therefore, metastatic melanoma cells expressing  
103 MET might scavenge HGF from the brain for activation of processes downstream of MET  
104 mediating survival and proliferation.

105 Here, we used transcriptome and methylome profiling to unravel the epigenetic and  
106 transcriptomic landscapes of MBM that featured infiltration of TAMs with emphasis on the

107 potential role of microglia in the activation of the HGF/MET receptor signaling pathway. The  
108 MET receptor inhibitors PHA-665752 and tivantinib (ARQ197) effectively blocked the growth  
109 of brain metastases derived cells (BMCs). Hence, targeting MET receptor signaling might  
110 serve as a potent therapeutic target for brain metastases lacking druggable BRAF<sup>V600</sup>  
111 mutations.

## 112 **Results**

### 113 **A microglia-specific gene cluster discriminates MBM**

114 Microglia are a unique population of antigen-presenting cells in the central nervous system  
115 (CNS) that are capable of clearing the brain of microbes, dead cells and protein  
116 aggregates<sup>16</sup>. Besides, microglia play a crucial role during injury repair and display an  
117 exceptional role in immune surveillance and tumor clearance<sup>17,18</sup>. Although the role of tumor-  
118 associated microglia and macrophages (TAMs) in primary brain tumors such as  
119 glioblastoma<sup>19-22</sup> has been intensively studied, their role in the progression of brain  
120 metastases remains poorly understood.

121 We performed immunohistochemistry (IHC) of our MBM cohort (Supplementary table 1  
122 and<sup>23</sup>) to determine the levels of activated, Iba1<sup>high</sup> TAMs. Although Iba1/AIF1 serves as a  
123 well-established marker, reactive microglia cannot be distinguished from brain infiltrated  
124 macrophages<sup>24</sup>. Initial studies of MBM revealed that Iba1/AIF1 levels classified tumors into  
125 highly and lowly TAM infiltrated (Figure 1a, Supplementary figure 1a). Moreover, we  
126 observed overlapping patterns of infiltration of Iba1<sup>high</sup> TAMs and CD3<sup>+</sup> T cells (Figure 1b). As  
127 CD3 only provided information about levels of T cell infiltration, we used the ESTIMATE  
128 algorithm<sup>25</sup> to gain insight into the overall degree of immune cell infiltration of MBM. In line  
129 with our previous observation, tumors with intensive TAM and T cell infiltration exhibited a  
130 high immune score (Pts 3, 4, 10, 12) whereas MBM with low levels of Iba1<sup>high</sup>/ CD3<sup>+</sup> cell  
131 infiltration (Pts 1, 2) or low expression of Iba1/AIF1 (Supplementary figures 1b, c) showed  
132 low immune scores (Figure 1c). As expected, brain metastases derived cell lines (BMCs)  
133 with absence of immune cells featured lowest scores (Supplementary figures 1b, c). The

134 brain has long been considered a sanctuary where tumor cells can grow undisturbed and  
135 protected from attack by immune cells. Therefore, we next investigated expression levels of  
136 Iba1/AIF1 in brain (MBM) and extracranial metastases (EM). We observed AIF1 expression  
137 in both as well as a high correlation with immune score (Figure 1d), suggesting a relationship  
138 between levels of infiltration of TAMs and immune cells not only in the brain. As high levels of  
139 immune cell/T cell infiltration are generally associated with good prognosis<sup>26</sup>, we determined  
140 the probability of survival related to Iba1/AIF1 expression of patient's with (study  
141 EGAS00001003672) and without (TCGA-SKCM) MBM. We observed beneficial effects of  
142 high Iba1/AIF1 levels in the TCGA cohort (HR=0.46 (0.35 – 0.62), logrank p=1.3e-07)  
143 (Figures 1e, f), however, Iba1/AIF1 level had no beneficial effects on the survival of MBM  
144 patients. Since no data on TAM-infiltrated MBM are available, we performed comparative  
145 methylome and transcriptome profiling of Iba1<sup>high</sup> (n=5-10) and Iba1<sup>low</sup> (n=2-6) tumors and  
146 identified a set of 417 differentially methylated genomic regions (DMRs) that corresponded to  
147 294 MBM expressed genes (Figure 1g) a core set of markers (n=31) sufficient to split tumors  
148 (Figure 1h; Supplementary tables 2, 3). Among them, we identified the integrin family  
149 member and gut-homing receptor ITGB7 -which we described in our previous study as a  
150 distinguishing mark between BRAF and NRAS mutant MBM<sup>23</sup> - and *APBB1IP* (amyloid b  
151 precursor protein-binding family b member 1 interacting protein). Both are associated with  
152 better prognosis in patients with colorectal cancer<sup>27,28</sup> and clustered with known TAM-  
153 associated genes such as *P2RY12* and *AIF1* (Figure 1h). Remarkably, all clustered tumors  
154 were associated with a high immune score. A correlation analysis of clustered genes  
155 revealed a high degree of correlation among each other (Figure 1i) and association with  
156 hepatocyte growth factor (HGF) that was recently connected with microglia activation<sup>13</sup>.  
157 However, only some of the identified markers within the gene cluster were specifically  
158 expressed in microglia but not in brain infiltrating macrophages or other brain cells such as  
159 *APBB1IP* (Figure 1j). The latter gene which has been identified as a conserved microglial  
160 gene<sup>29</sup> and binding partner of amyloid precursor protein (APP), Tau, 14-3-3g, and glycogen  
161 synthase kinase 3 b (GSK3 b) was associated with actin dynamics and retinoic acid

162 signaling<sup>30,31</sup>. Expression of *APBB1IP* was significantly (MBM: R=0.86, p<2.2e-16) correlated  
163 with immune score (Figure 1k) and survival of melanoma patients (Supplementary figures  
164 1d-e). Moreover, our survey identified a differentially methylated site (Supplementary table  
165 4) within the promoter of PD-L2 (*PDCD1LG2*) that may predict progression-free survival in  
166 melanoma patients receiving anti-PD-1 immunotherapy<sup>32</sup>. PD-L2 expression was associated  
167 with favorable survival (p=0.020) of patients with MBM (Supplementary figure 1f). We found  
168 additional genes among our cluster that were expressed in TAMs and significantly  
169 associated with immune score (Supplementary figures 1g-n).

170

### 171 **Expression of *ITGB7* serves as indicator of immune cell infiltration**

172 Recent studies have shown that *ITGB7* plays a critical role in the recruitment of T cells to the  
173 intestine and that downregulation of *ITGB7* is important in protecting intestinal tumors from  
174 attack by activated T cells<sup>27,33</sup>. Hence, we sought to investigate *ITGB7* in more detail. Mining  
175 of publicly available immune cell data (studies GSE146771<sup>34</sup>, DICE database<sup>35</sup>) revealed  
176 expression of *ITGB7* across different immune cell stages including naïve and memory  
177 subsets of T cells, B cells and NK cells (Figure 2a and Supplementary figure 2a). We found  
178 that *ITGB7* was rather expressed in MBM with infiltration of immune cells and particularly  
179 within immune cell dense areas (Supplementary figure 2b). Co-staining revealed  
180 accumulation of CD3<sup>+</sup> T cells as well as of Iba1<sup>high</sup> TAMs (Figure 2b). Ranking of MBM  
181 regarding levels of *ITGB7* expression showed co-occurrence in the expression of CD4,  
182 CD274, Sushi Domain Containing 3 (*SUSD3*) and *ITGB7* level (Figure 2c) and validated a  
183 possible, previously observed<sup>23</sup> correlation of *ITGB7* and *SUSD3*. Moreover *ITGB7*, *SUSD3*  
184 and *APBB1IP* showed expression across different immune cell types except for monocytes  
185 and NK cells (Supplementary figures 2c-f). Global (850k) methylome profiling uncovered four  
186 epigenetic regulation sites of *ITGB7* (Supplementary table 4) with two sites that were  
187 associated with expression levels and immune score (Figures 2d, left and center panel,  
188 Supplementary figure 3a), located in a proximal enhancer-like region (probe cg26689077) or  
189 near by the promoter of *ITGB7* (probe cg01033299). The latter site was also identified in the

190 TCGA-SKCM cohort. The sites did not correlate with the BRAF mutation status of MBM  
191 (Figures 2d, right panel) in contrast to additional two sites that were found within intergenic  
192 regions including an CpG island located between exons 4 and 5 (probes cg11510999 and  
193 cg18320160; Supplementary figures 3b-e).

194 Hence, methylome profiling of MBM identified two DMRs within the *ITGB7* gene that might  
195 serve as indicators of the degree of immune cell infiltration.

196 A recent study demonstrated that MBM feature a lower T cell content than matched  
197 extracranial metastases, however response rates to ICi of both were comparable<sup>36</sup>.  
198 Assuming that *ITGB7* expression might be crucial for T cell recruitment, we ascertained  
199 *ITGB7* levels in MBM (n=79) and EM (n=59; study EGAS00001003672). We observed that  
200 *ITGB7* was expressed in both metastatic subtypes and was significantly correlated (MBM:  
201 R=0.51, p=1.8e-06; EM: R=0.69, p=1.1e-09) with the tumor's immune scores (Figure 2e). As  
202 we suggest that *ITGB7* expression might indicate the degree of immune cell infiltration and  
203 possibly serve as indicator of response to ICi, we next performed correlation analysis of  
204 *ITGB7* and known markers of T cells and B cells. We observed a high concordance with  
205 immune cell-related but not tumor cell-related genes (*NGFR*, *MITF*, *MLANA*, *SLC45A2*) and  
206 correlation with expression of *PDCD1LG2* (PD-L2) and *SUSD3*, irrespective of the side of  
207 metastasis (Figures 2f, g). In line with previous observations, *ITGB7* was expressed in  
208 primary and metastatic tumors (TCGA-SKCM) and like *SUSD3* was associated with favored  
209 survival (Figure 2i). In summary, our survey identified a set of markers that are potentially  
210 associated with the level of TAM/immune cell infiltration, particularly *ITGB7* might serve as a  
211 marker for a favorable course of the disease.

212

213 **A signature-based deconvolution revealed MET receptor signaling in microglia-**  
214 **enriched MBM**



215 Our previous survey identified a set of markers that potentially characterize a molecular  
216 subset of MBM, likely showing a favorable course and response to ICI therapy<sup>37,38</sup>. To further  
217 characterize this set of tumors, we performed single-sample Gene set Enrichment-Analysis  
218 (ssGSEA) using defined immune-related and gene signatures specifying signaling processes  
219 such as MET receptor or STAT3 signaling among others that are reported to be involved in  
220 immune-response mechanisms (Supplementary table 5). We observed that MBM featuring a  
221 high immune score showed activation of MET and STAT3 signaling, increased tumor  
222 inflammation, stress and senescence (SenMayo<sup>39</sup>) (Figure 3a). Moreover, deconvolution  
223 revealed the presence of reactive microglia, astrocytes and immune cell subsets, among  
224 them stem cell-like CD8<sup>+</sup> T cells (TCF7)<sup>40</sup> in tumors, absent in BMCs. CD8<sup>+</sup> (TCF7) T cells  
225 are necessary for long-term maintenance of T cell responses and predicted positive clinical  
226 outcome<sup>41,42</sup>. Signatures clearly discriminated MBM and BMCs and reinforced the differences  
227 of Iba1<sup>high</sup> (Pts 3, 4) and Iba1<sup>low/neg</sup> (Pts 1, 2) tumors. We therefore suggest that the activation  
228 of MET- or STAT3-mediated signaling processes or those related to stress/senescence or  
229 inflammation strongly depend on the composition of the tumor microenvironment, likely  
230 determining the response to therapeutic interventions. Although infiltration of TAMs is not  
231 evident in all MBM, microglia infiltration seems to be an early occurring process observed  
232 ~21d after intracranial injection of BMCs into brains of immune compromised Crl:CD1-  
233 Foxn1<sup>nu</sup> mice<sup>23</sup> (Figure 3b). Moreover, we observed activation of Stat3 signaling in tumor  
234 adjacent cells (Figure 3b), suggesting that brain microenvironmental cells are activated after  
235 a short time of tumor-stroma interaction and establish an inflammatory environment. We  
236 performed ssGSEA and applied the above mentioned signatures and observed a  
237 comparable pattern of enrichment in a more comprehensive and independent set of MBM  
238 (study EGAS00001003672<sup>43</sup>, n=79 MBM) (Supplementary figure 4a).

239 HGF or scatter factor (SF) is the only identified ligand of MET, plays a pivotal role during  
240 neural development, regulating growth and survival of neurons<sup>15,44</sup> and likely serves as  
241 inducer of reactive microglia by an autocrine loop in response to trauma or  
242 neurodegenerative disorders<sup>13</sup>. Therefore, MET expressing, brain colonizing melanoma cells

243 may benefit and take advantage of the HGF-controlled systems naturally occurring in the  
244 brain. We observed HGF expression among tumors of different data sets comprising MBM,  
245 EM and primary tumors (studies EGAS00001005976; TCGA-SKCM; EGAS00001003672)  
246 with no significant difference of HGF levels in tumor subsets (Figures 3d, e). Investigation of  
247 immune cell and brain cell data (DICE database<sup>35</sup> and study GSE73721<sup>45</sup>) revealed high  
248 expression of HGF in monocytes and astrocytes (Figures 3f, g), suggesting a potential role of  
249 different stroma cell populations for activating HGF/MET signaling in brain-infiltrating tumor  
250 cells. Assuming that the degree of microglia infiltration determines signaling processes in  
251 MBM cells, we explored expression levels of MET signaling-associated genes in tumors with  
252 high and low level of infiltrated TAMs and found levels of HGF, PIK3CG, PTK2B, STAT3 and  
253 MAP4K1 significantly correlated with microglia score (Supplementary figure 4c-e) that was  
254 defined as average expression level or  $\beta$ -value of microglia markers *APBB1IP*, *SYK*, *HCK*  
255 and *P2RY12* (Supplementary table 6).

256 HGF might be released by immune cells as well as homeostatic and reactive microglia or  
257 astrocytes. We surveyed the Seattle Alzheimer's Disease Brain Atlas which is implemented  
258 in the Allen brain atlas database (<https://portal.brain-map.org/>) and observed that dementia  
259 fostered expansion of microglia with increased expression of HGF (Figure 3h, center and  
260 right panels). Reactive microglia and immune cell released HGF might hence be responsible  
261 for activation of growth factor/survival signaling in adjacent tumor cells. In line with previous  
262 studies, we observed a significant correlation of HGF expression with immune score in brain  
263 (BM,  $R=0.49$ ,  $p=5.3e-06$ ) and extracranial metastases (EM,  $R=0.41$ ,  $p=1.5e-03$ ), (Figure 3i).

264

### 265 **Expression and activation of MET receptor classifies a molecular subset of MBM**

266 Understanding the molecular mechanisms that establish cellular dependencies and thus  
267 control the development and maintenance of brain metastases is critical for their therapeutic  
268 manipulation. Recently, we identified that the expression of Ecad and NGFR sufficiently  
269 discriminated molecular subsets of MBM<sup>23</sup>. These subsets likely distinctly interact with  
270 microenvironmental cells and respond to therapeutics (Figure 4a). To identify potential

271 druggable targets, we surveyed the pan-MBM, NGFR and Ecad-specific gene sets for cell  
272 surface receptors that may serve as crucial key factors that control tumor cell maintenance  
273 and expansion and identified 24 receptors that distinguished Ecad<sup>+</sup> and NGFR<sup>+</sup> tumors  
274 (Figure 4b). Particularly ADIPOR1 (adiponectin receptor 1, p=1.9e-02), SIRPA (signal  
275 regulatory protein alpha, p=1.1e-05) and PLXNC1 (plexin C1) showed significantly increased  
276 expression in Ecad<sup>+</sup> MBM and EM but comparable levels among MBM and EM (Figure 4c).  
277 In addition, Ecad<sup>+</sup> MBM featured increased levels of MET receptor in (p=1.4e-04). MET was  
278 significantly (p=2.7e-05) higher expressed in MBM than EM (Figure 4d, left and center  
279 panels). The MET tyrosine kinase receptor pathway serves as a potent survival and  
280 maintenance factor for MBM and might be a promising therapeutic target<sup>46</sup>. MET expression  
281 was associated with increased cell cycle progression and proliferation (Figure 4d, right panel)  
282 and defined yet another subset of MBM (Figure 4e). Next we assessed whether expressed  
283 MET indeed participated in active signaling processes. Phosphorylation of MET at tyrosine  
284 residues 1234/1235 (pMET<sup>Y1234/1235</sup>) is critical for kinase activation and initiation of  
285 downstream processes and was evident in nearly all MET<sup>high</sup> MBM investigated, independent  
286 of the BRAF mutation status (Figures 4f, g). MET receptor alterations are evident in 9 % of all  
287 SKCM melanoma cases, including amplification as observed in 1.13 – 17.2% or 11% of  
288 melanoma (TCGA-SKCM, study by Ramani et al.<sup>47</sup>). However, targeted DNA sequencing  
289 (TargetSeq) and fluorescence in-situ hybridization (FISH) revealed absence of MET  
290 activating mutations and a tendential MET amplification in only one case (Pat 5,  
291 Supplementary figure 5a, b). However, all but one tumor (Pat 14) showed high polysomy. As  
292 we assume that environmental cells foster activation of MET receptor signaling in a subset of  
293 tumor cells, we performed co-IHC for pMET<sup>Y1234/1235</sup> and Iba1. We observed pMET<sup>Y1234/1235</sup>  
294 positive tumor cells in close proximity to Iba1<sup>high</sup> TAMs (Figure 4h), though MET receptor was  
295 not activated in Iba1<sup>high</sup> microglia that resided in adjacent normal tissue (Supplementary  
296 figure 5c, upper panel). However, MET receptor activation was also evident in scattered  
297 tumor cells in the absence of adjacent Iba1<sup>high</sup> TAMs (Supplementary figure 5c, lower panel)  
298 suggesting paracrine mechanisms or additional sources of HGF such as immune cells or

299 astrocytes. Considering that HGF levels, like those of other growth factors provided by  
300 stromal cells, might depend on spatial factors, we examined the Allan Brain Atlas database  
301 and found that HGF is comparably expressed in different brain sections (frontal lobe (FL),  
302 parietal lobe (PL), temporal lobe (TL), occipital lobe (OL)) but is lowly abundant in the  
303 brainstem (pons) (supplemental Figure 5d). The spatially dependent expression of growth  
304 factors in the brain may therefore determine the dependencies of the tumor cells.

305

### 306 **Interferon signaling determines response of MBM to immune checkpoint inhibitor** 307 **therapy**

308 Interferon-gamma signaling has been identified as an important mechanism for upregulation  
309 of PD-L1 on melanoma cells and escape from immune recognition. On the other hand,  
310 recent studies uncovered that high interferon-gamma-related gene expression signature  
311 scores (IFN- $\gamma$  score) were associated with low risk of melanoma relapse from neoadjuvant  
312 ipilimumab plus nivolumab therapy<sup>48,49</sup>.

313 In our recent study, we observed significant enrichment of interferon and inflammatory  
314 response (“Hallmark”, MsigDB<sup>50</sup>) signatures in MBM with high level of tumor infiltrating  
315 lymphocytes (TIL<sup>high</sup>)<sup>23</sup> that have been attributed with favored survival in a pre-clinical  
316 melanoma model<sup>49</sup>. We found overlapping expression of *ITGB7*, *SUSD3* and *HGF* and  
317 Hallmark interferon-response genes, separating MBM of our cohort and MBM of study  
318 EGAS00001003672 (Figure 4i, Supplementary figure 6a). Expression of *ITGB7* significantly  
319 correlated with levels of interferon regulatory factor 1 (IRF1) and IRF8 in MBM (BM) and  
320 extracranial metastases (EM) of study EGAS00001003672 (Supplementary figure 6b-d).  
321 Moreover, we observed high correlation of levels of *HGF*, *IRF1* and *IRF8* in MBM  
322 (Supplementary figure 6e). As microglia serve as a source of soluble receptor ligands such  
323 as Hgf, we next surveyed data of interferon-gamma treated (1 U/mL IFN $\gamma$ , 24h) murine  
324 microglia cells (BV2, GSE132739). Indeed, we found significant upregulation of *Itgb7* (p =  
325 2.9e-03) and *Hgf* (p=4.4e-02) but downregulation of *Susd3* (p=4.0e-02) in BV2 cells  
326 (Supplementary figure 6f). For control, we investigated levels of known interferon-responsive

327 genes that were significantly increased 24h after interferon treatment, *Mx1* ( $p=1.2e-02$ ), PD-  
328 *L1/Cd274* ( $p=3.6e-02$ ), *Irf1* ( $p=3.1e-02$ ) *Cxcl9* ( $p=4.0e-03$ ) and *Aif1* ( $p=3.9e-04$ )  
329 (Supplementary figure 6g). In order to classify MBM of our study into anti-PD-L1 responsible  
330 and non-responsible and for linking *ITGB7*, *SUSD3* and *HGF* with therapy response, we  
331 performed ssGSEA and applied interferon responsive and additional immune response gene  
332 signatures (of study GSE186344<sup>51</sup>). Our survey validated that *ITGB7*, *SUSD3* and *HGF* were  
333 highly expressed in MBM that featured enrichment of interferon responsive genes/signatures  
334 (Pts. 3-6, 12; Supplementary figure 6h).

335

336 Hence, we suggest that *ITGB7*, *SUSD3* and *HGF* like *PD-L1* are among the interferon-  
337 regulated genes triggered by immune cell-released interferon-gamma and may be involved in  
338 immune response mechanisms of MBM.

339

#### 340 **The targeting of MET receptor serves as a promising strategy to control MBM growth**

341 Although a subset of MBM exhibit immune cell subset enrichment and interferon response  
342 signatures and respond to ICI therapy, MET-expressing brain metastatic melanoma cells  
343 may benefit from HGF released by stromal cells to drive progression. Hence, activation of  
344 MET signaling may depend on the degree of tumor-stroma interaction, possibly  
345 counteracting the beneficial impact of immune checkpoint inhibition (ICI). Resistance-  
346 mediating processes include the phosphorylation of ribosomal protein S6 (pS6), which is  
347 downstream of MET and mTOR signaling<sup>52</sup> and was observed in progressive BRAFi-resistant  
348 melanomas<sup>53,54</sup>.

349 We assessed pS6 phosphorylation of serine residues 235/236 and found co-occurrence of  
350 activated MET receptor and of pS6<sup>235/236</sup> in MITF positive tumors (Figure 5a and  
351 Supplementary figures 7a, b). Moreover, pS6 phosphorylation was evident in a BRAF<sup>wt</sup>  
352 (T2002) and mutated (V600E, BMC53) cell lines probably suggesting a general activation of  
353 pS6 signaling irrespective of the presence of mutated BRAF (Figure 5b). As MET signaling  
354 might serve as mediator of a resistance-mediating program, we assessed the efficacies of

355 the ATP-competitive inhibitor PHA-665752 and the non-ATP-competitive, clinical phase I/II  
356 MET receptor inhibitor (METi) tivantinib (ARQ197) in BMCs that showed variable levels of  
357 MET expression (Figure 5c and Supplementary figure 7c). ARQ197 failed to improve the  
358 outcome and overall survival of patients with hepatocellular carcinoma<sup>55</sup> but may potentially  
359 be effective in melanoma patients. The initial testing revealed a general response of BMCs  
360 (BMC1-M1, BMC53), T2002 cells and conventional cell lines (A375, A2058, MeWo) to both  
361 inhibitors irrespective of the BRAF mutation status (Figures 5d, e). As we observed a  
362 mutually exclusive rather than co-expression of MET receptor and NGFR (nerve growth  
363 factor receptor), we tested whether the manipulation of NGFR levels might affect the  
364 response to PHA-665752 (PHA). We observed that overexpression of NGFR in A375 cells  
365 (A375<sup>NGFR</sup>) sensitized to METi compared to RFP expressing control (A375<sup>RFP</sup>) or MeWo cells  
366 (Figure 5f). Next, we asked whether METi targeting may serve as alternative therapeutic  
367 strategy for BRAFi resistant (BMC4) or cells with non-BRAF<sup>V600</sup> mutations (BMC2) showing  
368 only moderate or no response to dabrafenib (Figure 5g) as indicated by IC<sub>50</sub> values (BMC4,  
369 IC<sub>50</sub> = 226.4 nM and BMC2, IC<sub>50</sub> = 3029.5 nM). The broad range (1nM – 10µM) testing of  
370 tivantinib in BMCs, T2002 and conventional melanoma cells and PHA in BMCs revealed that  
371 all cell lines responded to both METi, irrespective of the mutation status. However, we  
372 observed that the non-(brain) metastatic cell lines A375, A2058, and T2002 were more  
373 sensitive to treatment with tivantinib than BMCs (Figures h-j, Supplementary figure 7d). The  
374 median IC<sub>50</sub> value of BMCs was ~600 nM (range: 406.5 – 800.1). Cell lines lacking BRAF  
375 and NRAS mutations (MeWo, T2002) showed highest responses to tivantinib (Figure 5k).

376

377 In summary, brain metastatic as conventional melanoma cell lines responded to METi,  
378 suggesting that targeting of MET signaling might be a promising tool for the treatment of non-  
379 BRAF<sup>V600</sup> and BRAF<sup>V600</sup> mutated MBM that acquired resistance to BRAFi or for combinatorial  
380 of METi and ICi in NRAS mutated tumors.

381

382

## 383 **Discussion**

384 The spatiotemporal development of primary and secondary brain tumors is strongly  
385 determined by the crosstalk of tumor and brain micronenvironmental cells, particularly  
386 macrophages, astrocytes and microglia<sup>56</sup> and the consequential activation of inflammatory  
387 processes<sup>57</sup>. Although the neuro-inflammatory processes that are activated alongside  
388 development and progression of primary brain tumors such as glioblastoma have been  
389 intensively studied, the mechanisms that accompany emergence of brain metastases on the  
390 other side are not well investigated.

391 Here, we used combined transcriptome and methylome profiling to unravel the molecular  
392 features of MBM of different progression stages showing high and low level of tumor-  
393 associated macrophages/microglia (TAMs) infiltration, irrespective of the phenotype (Ecad,  
394 NGFR). Generally, TAMs foster development and progression of primary brain tumors<sup>58,59</sup>,  
395 however their functional role in MBM may be different. We observed that MBM containing a  
396 high proportion of TAMs were associated with a high immune score and infiltration of CD3<sup>+</sup> T  
397 cells. The profiling of Iba1/AIF1<sup>high</sup> tumors revealed a cluster of genes, among them *ITGB7*,  
398 *APBB1IP* as *SUSD3* and *PD-L2*, that were widely expressed among immune cell subtypes  
399 and previously associated with increased immune T cell infiltration<sup>23,27,28,33</sup> and favored  
400 outcome. Previous mouse studies demonstrated a pivotal role of *ITGB7* for intestinal T cell  
401 recruitment and correlated low levels of *Itgb7* with colorectal cancer progression and  
402 maintenance of intestinal stem cells via Ecad-mediated interaction<sup>27,33</sup>. However, we  
403 observed strong protein expression of *ITGB7* in immune cells adjacent to tumor cells of  
404 Ecad<sup>+</sup> and NGFR<sup>+</sup> tumors, suggesting a broader function of *ITGB7* in different subtypes of  
405 metastases and cancers. Enhanced expression of *ITGB7* might be a prerequisite for immune  
406 cell invasion. Therefore, epigenetic marks that correlate with the expression of *ITGB7* and  
407 other genes mentioned above may be of prognostic importance, and the expression of these  
408 markers could determine the pathways of intracranial progression.

409 As previously described for the Ecad<sup>+</sup> and NGFR<sup>+</sup> subtypes of MBM, whether tumors are  
410 enriched or depleted in TAMs and immune cell subsets is critical and may determine  
411 response to therapeutic intervention. The subsequent ssGSEA-based characterization of  
412 MBM of studies performed by us and others revealed molecular programs fostering or  
413 accompanying the TAM<sup>+</sup>/TIL<sup>+</sup> tumor subtype. TAM<sup>+</sup>/TIL<sup>+</sup> tumors featured activation of MET  
414 and STAT3 signaling, increased stress response, tumor inflammation, senescence and  
415 activation of microglia and astrocytes but also activated interferon signaling. STAT3  
416 activation in tumor-adjacent astrocytes in response to brain damage or tumor cells is well-  
417 investigated process<sup>60,61</sup> and was rapidly induced in response to brain infiltrating BMCs.  
418 Hence, enrichment of STAT3 signature genes was likely attributed to tumor-adjacent  
419 astrocytes and infiltrated immune cells<sup>62</sup>.

420

421 The HGF/MET receptor signaling plays a pivotal role during brain development and neuro-  
422 regeneration, homeostasis of microglia and neurons<sup>14,44</sup> but is also involved in microglia  
423 activation in response to trauma<sup>13,44,63</sup>. Brain infiltrating melanoma cells hence may engage  
424 the HGF/MET signaling of brain cells and utilize for regulation of survival and proliferation.  
425 We observed expression of MET receptor in the subset of E-cadherin (Ecad) expressing  
426 tumors<sup>23</sup>, suggesting that Ecad<sup>+</sup> but not NGFR<sup>+</sup> cells may depend on HGF/MET signaling. As  
427 we observed that HGF is expressed by immune cell subsets and homeostatic or reactive  
428 astrocytes and microglia, we investigated the level of activated/phosphorylated MET receptor  
429 in TAM-adjacent tumor cells. We found that tumor cells but not Iba1<sup>high</sup> TAMs that resided in  
430 tumor cell-free adjacent stroma showed activation of MET, however MET was also activated  
431 in the absence of adjacent microglia in some tumor cells, suggesting a paracrine effect of  
432 HGF. In line with our previous study<sup>23</sup>, we observed enrichment of interferon-response  
433 signatures in the subset of TIL<sup>high</sup>/immune score (IS)<sup>high</sup> tumors. We observed enrichment of  
434 interferon-response genes in MBM with high levels of ITGB7 expression and observed  
435 significant response of Itgb7 and Hgf among known interferon-inducible genes such as  
436 Cd274<sup>64</sup> and Mx1<sup>65</sup> in interferon-gamma treated BV2 murine microglia cells (unpublished



437 study GSE132739). Hence, T cell-provided interferon-gamma might not only induce  
438 expression of Cd274/PD-L1 but may also activate expression of HGF and ITGB7. Therefore,  
439 autocrine MET receptor signaling might be triggered in response to immune cell released  
440 interferon-gamma and/or paracrine activation of MET signaling may occur via (INFG-  
441 activated) reactive glia-released HGF.

442 Our study bridges the gap between the immune cell phenotype of MBM and the activation of  
443 potentially therapeutic counteracting signaling pathways. The infiltration of TAMs and  
444 immune cells thus represents a double-sided sword and on the one hand is associated with  
445 an effective response to immune checkpoint inhibitors, but on the other hand can support the  
446 growth of MET expressing tumor cells via secreted factors such as HGF.

447 Therefore, we finally assessed the potential role of small molecule inhibitors of MET receptor  
448 (METi) for targeting of MBM that lack druggable BRAF<sup>V600</sup> mutations or developed refractory  
449 disease. To this end, we took advantage of well-characterized BMCs serving as *in vitro*  
450 model systems. We observed that the ATP-competitive inhibitor PHA-665752 and the non-  
451 ATP-competitive, clinical phase II inhibitor ARQ197 (tivantinib) elicited response in BMCs  
452 and conventional melanoma cell lines irrespective of the BRAF/NRAS mutation status.  
453 However, although being effective at doses of 100 – 200 nM in MeWo and A375 cells,  
454 ARQ197 showed a median IC<sub>50</sub> value of ~1 μM in BMCs, suggesting a general difference  
455 among brain metastatic and long-term maintained conventional cell lines established from  
456 either non metastatic (A375) or locally metastatic (MeWo) cells.

457 In summary, we have shown that MET receptor signaling is active in a subset of MBM,  
458 conferring a survival/growth benefit independent of BRAF/NRAS mutation status. MET  
459 activation may occur in response to HGF released by TAM/immune cells and could  
460 counteract therapeutic interventions. Furthermore, we suggest interferon-induced expression  
461 of HGF in tumor cells triggered by interferon-gamma provided by stromal cells mediates  
462 autocrine activation of MET-signaling tumor cells (Figure 6). In addition, we demonstrated  
463 that methylome profiling of MBM has high potential to identify gene regulatory sites that may

464 predict favorable progression of intracranial disease. In the present study, we identified  
465 epigenetic regulatory sites in a group of genes comprising *ITGB7*, *APBB1IP*, *SUSD3* and  
466 PD-L2 (*PDCD1LG2*).

467

#### 468 **Limitations of the study**

469 The present study is not without limitations. Although we suggested that HGF/MET signaling  
470 is activated in tumor cells in close proximity to infiltrated microglia, we have not provided  
471 evidence that growth of established brain tumors and phosphorylation of MET decreases in  
472 response to METi. Moreover, whether METi are capable of passing the blood-brain barrier  
473 and not affect normal homeostatic processes e.g. those crucial for neuron survival needs to  
474 be investigated.

475

#### 476 **Methods**

##### 477 **Patient cohorts**

478 All procedures performed in this study were in accordance with the ethical standards of the  
479 respective institutional research committees and with the 1964 Helsinki declaration and its  
480 later amendments or comparable ethical standards. All patients gave written informed  
481 consent for the collection and scientific use of tumor material which was collected at the  
482 Biobank of the Charité – Comprehensive Cancer Center (CCCC). The study was approved  
483 by the Ethics Committee of the Charité (EA1/152/10; EA1/107/17; EA4/028/18 and  
484 EA1/107/17 and EA1/075/19) and Universitätsmedizin Greifswald (BB 001/23).

485

##### 486 **Cultivation of MBM-derived and conventional melanoma cell lines**

487 All cell lines were cultured as previously reported<sup>23</sup>. Briefly, all brain metastases-derived cell  
488 lines (BMCs) and conventional melanoma cell lines were kept at 37°C/ 5% CO<sub>2</sub> and 95%  
489 humidity in cell culture medium (DMEM, 4.5 g/L glucose, stabilized glutamine/GlutaMax,

490 pyruvate, Gibco/ThermoFisher) supplemented with 10% fetal bovine (FBS, Gibco) serum and  
491 1% penicillin/streptomycin (P/S) (Gibco/ThermoFisher) and routinely passaged. BMCs were  
492 established from intraoperative tumors as previously reported<sup>23</sup>.

493

#### 494 **Live cell imaging-based drug sensitivity assays**

495 Drug treatments were performed 24 h after seeding of 2,500-5,000 cells/96-well in 100  $\mu$ l  
496 medium. The response of BMCs and conventional melanoma cell lines to dabrafenib, PHA-  
497 665752 or ARQ197 (all purchased from Selleckchem) in a range of 1nM-10 $\mu$ M of eight  
498 technical replicates was determined by live cell imaging. Images were taken every three  
499 hours using a 10x objective and the general label-free mode, two pictures of eight technical  
500 replicates per condition were taken. Drug response was assessed by changes in the cellular  
501 density over time. The cell density was determined by a confluence mask tool as part of the  
502 IncucyteS3 software. IC50 values were calculated by curve-fitting ([https://search.r-](https://search.r-project.org/CRAN/refmans/REAT/html/curvefit.html)  
503 [project.org/CRAN/refmans/REAT/html/curvefit.html](https://search.r-project.org/CRAN/refmans/REAT/html/curvefit.html)) based on confluence measurements at  
504 day 3.

#### 505 **In vivo experiments**

506 All animal experiments were performed in accordance with the German Animal Protection  
507 Law under the permission number G0130/20 obtained via the Berlin Ministry of Health and  
508 Social Affairs (LaGeSo). ARRIVE 2.0 Guidelines were strictly followed and performed as  
509 previously reported<sup>23</sup>. Briefly, 2.5x10<sup>4</sup> BMC1-M4 and BMC2 cells were stereotactically  
510 inoculated into brains of female Crl:CD1-Foxn1<sup>nu</sup> nude mice (8-9 weeks of age, 24-26g,  
511 Charles River Laboratories) were with using a 1 $\mu$ l Hamilton syringe and a stereotactic frame  
512 as described previously<sup>66</sup>. Tumor growth was tracked by MRI and animals were sacrificed by  
513 perfusion with 4% PFA in deep anesthesia after tumors reached a volume of 20 mm<sup>3</sup>.  
514 Following, whole brains were removed, dehydrated, paraffin embedded and sections of 2  $\mu$ m  
515 were used for downstream analyses.

516

517

518 **RNA isolation and sequencing**

519 Isolation of total RNA from snap frozen tumors and RNA sequencing was performed as  
520 previously reported<sup>23</sup>. Briefly, 100 ng of total RNA was used for library preparation with  
521 TruSeq Stranded total RNA Sample Preparation-Kit and Ribo-Zero Gold Kit (Illumina).  
522 Paired-end (2x100 bp) sequencing of RNA libraries with integrity numbers (RIN)  $\geq 7$  was  
523 performed on NovaSeq6000 platform at Cegat GmbH, Tuebingen (Germany). Following  
524 demultiplexing of sequenced reads and adapter trimming<sup>67</sup>, FASTQ files were obtained. Raw  
525 counts of protein-coding genes were normalized using the DESeq2  
526 ([https://bioconductor.org/packages/](https://bioconductor.org/packages/release/bioc/html/DESeq2.html) release/bioc/html/DESeq2.html) package<sup>68</sup>. Differential  
527 expression of genes between groups was determined after fitting models of negative  
528 binomial distributions to the raw counts. Raw p-values were FDR (false discovery rate)-  
529 adjusted for multiple testing and a value below 0.05 for the adjusted p-values were used to  
530 determine significant differentially expressed genes.

531

532 **Gene-set enrichment GSEA/Single-sample GSEA/Scores**

533 GSEA was performed using the most current BROAD javaGSEA standalone version  
534 (<http://www.broadinstitute.org/gsea/downloads.jsp>) and gene signatures of the molecular  
535 signature database MsigDB<sup>50,69</sup>, v7.4. In addition, we performed GSVA/ssGSEA using R  
536 packages GSVA<sup>70</sup>, GSRI, GSVAdata and org.Hs.eg.db and a customized collection of gene  
537 signatures including the signatures provided by Biermann et al.<sup>71</sup> and own signatures as  
538 defined by selected Ecad<sup>23</sup>, NGFR<sup>23</sup>, microglia or TME core genes (this study). All gene  
539 signatures are shown in Supplementary table 5. Microglia scores were defined as the mean  
540  $\beta$ -value of probes cg24400465 (APBB1IP), cg05128364 (SYK), cg21704050 (P2RY12) and  
541 cg03498995 (HCK) or expression levels (log<sub>2</sub> FPKM) of these markers. The proliferation  
542 index in Figure 4d was defined as mean expression level of the cell cycle regulators PCNA,  
543 MKI67, CCNB1 and CCNB2.

544

545

546 **Fluorescence in situ hybridization (FISH)**

547 FISH analysis was performed on 4 µm sections of FFPE blocks. Slides were deparaffinized,  
548 dehydrated and incubated in pre-treatment solution (Dako, Denmark) for 10 min at 95–99°C.  
549 Samples were treated with pepsin solution for 6 min at 37°C. For hybridization, a Vysis MET  
550 SpectrumRed/ Vysis CEP 7 (D7Z1) SpectrumGreen Probe (Abbott, Chicago, USA) was  
551 used. Incubation took place overnight at 37°C, followed by counterstaining with 4,6-  
552 diamidino-2-phenylindole (DAPI). For each case, signals were counted in 50 non-overlapping  
553 tumor cells using a fluorescence microscope (BX63 Automated Fluorescence Microscope,  
554 Olympus Corporation, Tokyo, Japan). Computer-based documentation and image analysis  
555 was performed with the SoloWeb imaging system (BioView Ltd, Israel). MET high-level  
556 amplification (MET FISH+) was defined as (a) MET/CEN7 ratio  $\geq 2.0$ , (b) average MET copy  
557 number/cell  $\geq 6$  or (c)  $\geq 10\%$  of tumor cells with  $\geq 15$  MET copies/cell as described in  
558 Schildhaus et al<sup>72</sup>.

559

560 **Quantitative real-time RT-PCR**

561 RNA isolation from frozen cell pellets was performed with the RNeasy Mini Kit (Qiagen,  
562 Germany) and, following the manufacturers protocol as previously reported<sup>23</sup>.qRT-PCR was  
563 carried out on a Step one plus PCR cycler (Applied Biosystems, Germany) for 30–40 cycles.  
564 Primers were designed for 55–60°C annealing temperatures. Relative expression levels were  
565 calculated with the  $\Delta\Delta CT$  method<sup>73</sup>, normalized to  $\beta$ -actin. Primer sequences are shown in  
566 Supplementary table 7.

567

568 **Immunohistochemistry (IHC)/Immunofluorescence (IF)**

569 Automated immunohistochemical staining was performed on formalin-fixed, paraffin-  
570 embedded (FFPE) tissue sections using the BenchMark Ultra (Ventana) autostainer. The  
571 following primary antibodies were used: CD3 (anti-CD3 $\epsilon$ , Agilent, catalog number:  
572 #A045201-2, rabbit, dilution: 1:100), pMET (phospho-MET, Tyr1234/1235, Cell signaling,

573 catalog number: #3077, rabbit, dilution: 1:100), pS6 (phospho-S6 ribosomal protein  
574 Ser235/236, Cell signaling, catalog number: #2211, rabbit, dilution: 1:100), IBA1 (IBA1/AIF-1,  
575 ionized calcium-binding adaptor molecule 1, Cell signaling, catalog number: #17198, rabbit,  
576 dilution: 1:100), ITGB7 (Integrin beta 7, Thermo Fisher, catalog number: #BS-1051R, rabbit,  
577 dilution: 1:100) and pSTAT3 (phospho-STAT3, Tyr705, Cell signaling, catalog number:  
578 #9145, rabbit, dilution: 1:100) and MITF (clones C5 $\alpha$ + $\alpha$ D5, Zytomed, catalog number:  
579 Z2161MP, mouse, dilution: 1:100). Primary antibodies were applied and developed using the  
580 iVIEW DAB Detection Kit (Ventana Medical Systems) or the ultraView Universal Alkaline  
581 Phosphatase Red Detection Kit (Ventana Medical Systems). All slides were counterstained  
582 with hematoxylin for 8 minutes. IF of mouse brain sections was performed with IBA1  
583 (IBA1/AIF-1, ionized calcium-binding adaptor molecule 1, Cell signaling, catalog number:  
584 #17198, rabbit, dilution: 1:100), KBA.62, NovusBiologicals, catalog number: NBP2-45285,  
585 mAb mouse, 1:100; GFAP-AlexaFluor594, BioLegend, catalog number: 644708, mAb  
586 mouse.

587

## 588 **Data availability**

589 Whole transcriptome and methylome data were deposited in the European Genome-  
590 Phenome Archive (EGA), under accession numbers EGAS00001005975,  
591 EGAS00001005976 (<https://ega-archive.org/studies/>). The data are available under  
592 controlled access. Supplementary tables of our recent study have been deposited at Zenodo  
593 (<https://doi.org/10.5281/zenodo.10006881>). Supplementary tables of our previous study  
594 containing a full list of patient's characteristics (Supplementary table 1) have been deposited  
595 at Zenodo (<https://zenodo.org/record/7013097> and <https://doi.org/10.5281/zenodo.7249214>).

596

597 **Author contributions**

598 TR performed data analyses, prepared figures and wrote the manuscript; ES collected  
599 tumors, established BMCs and performed experiments; KP performed histological analyses;  
600 MEW, SN and HWSS performed craniotomy and provided MBM; AV performed experiments/  
601 drug response assays; HR provided expertise on microglia markers; AL performed MET-  
602 FISH analyses; SKR provided funding; KJ performed bioinformatics data analysis and  
603 expertise on data analysis; JR wrote the manuscript, provided resources and funding. All  
604 authors have read and agreed to the published version of the manuscript.

605

606 **Competing interests**

607 The authors declare no conflicting interests.

608

609 **Funding**

610 JR is an alumnus of the BIH-Charité Clinical Scientist Program funded by the Charité –  
611 Universitätsmedizin Berlin and the Berlin Institute of Health. We thank the German Cancer  
612 Consortium (DKTK), Partner site Berlin for technical support. AV received funding by the  
613 ÖAW (DOC Fellowship: DOC/26523).

614

615 **Acknowledgments**

616 We gratefully thank Cathrin Müller for excellent technical assistance.

617

618

619

620

621

622

- 624 1 Redmer, T. Deciphering mechanisms of brain metastasis in melanoma - the gist of the  
625 matter. *Mol Cancer* **17**, 106, doi:10.1186/s12943-018-0854-5 (2018).
- 626 2 Srinivasan, E. S., Deshpande, K., Neman, J., Winkler, F. & Khasraw, M. The microenvironment  
627 of brain metastases from solid tumors. *Neurooncol Adv* **3**, v121-v132,  
628 doi:10.1093/nooncol/vdab121 (2021).
- 629 3 Holt, M. G. Astrocyte heterogeneity and interactions with local neural circuits. *Essays*  
630 *Biochem* **67**, 93-106, doi:10.1042/ebc20220136 (2023).
- 631 4 Hilscher, M. M. *et al.* Spatial and temporal heterogeneity in the lineage progression of fine  
632 oligodendrocyte subtypes. *BMC Biology* **20**, 122, doi:10.1186/s12915-022-01325-z (2022).
- 633 5 Li, Y. *et al.* Decoding the temporal and regional specification of microglia in the developing  
634 human brain. *Cell stem cell* **29**, 620-634 e626, doi:10.1016/j.stem.2022.02.004 (2022).
- 635 6 Tan, Y.-L., Yuan, Y. & Tian, L. Microglial regional heterogeneity and its role in the brain.  
636 *Molecular Psychiatry* **25**, 351-367, doi:10.1038/s41380-019-0609-8 (2020).
- 637 7 Liddelow, S. A. & Barres, B. A. Reactive Astrocytes: Production, Function, and Therapeutic  
638 Potential. *Immunity* **46**, 957-967, doi:10.1016/j.immuni.2017.06.006 (2017).
- 639 8 Bennett, M. L. & Viaene, A. N. What are activated and reactive glia and what is their role in  
640 neurodegeneration? *Neurobiol Dis* **148**, 105172, doi:10.1016/j.nbd.2020.105172 (2021).
- 641 9 Tan, Y. L., Yuan, Y. & Tian, L. Microglial regional heterogeneity and its role in the brain. *Mol*  
642 *Psychiatry* **25**, 351-367, doi:10.1038/s41380-019-0609-8 (2020).
- 643 10 Mathys, H. *et al.* Temporal Tracking of Microglia Activation in Neurodegeneration at Single-  
644 Cell Resolution. *Cell Rep* **21**, 366-380, doi:10.1016/j.celrep.2017.09.039 (2017).
- 645 11 Schwartz, H. *et al.* Incipient Melanoma Brain Metastases Instigate Astrogliosis and  
646 Neuroinflammation. *Cancer Res* **76**, 4359-4371, doi:10.1158/0008-5472.CAN-16-0485 (2016).
- 647 12 Colombo, E. & Farina, C. Astrocytes: Key Regulators of Neuroinflammation. *Trends Immunol*  
648 **37**, 608-620, doi:10.1016/j.it.2016.06.006 (2016).
- 649 13 Rehman, R. *et al.* Met/HGFR triggers detrimental reactive microglia in TBI. *Cell Rep* **41**,  
650 111867, doi:10.1016/j.celrep.2022.111867 (2022).
- 651 14 Yamagata, T. *et al.* Hepatocyte growth factor specifically expressed in microglia activated Ras  
652 in the neurons, similar to the action of neurotrophic factors. *Biochemical and biophysical*  
653 *research communications* **210**, 231-237, doi:10.1006/bbrc.1995.1651 (1995).
- 654 15 Nicoleau, C. *et al.* Endogenous Hepatocyte Growth Factor Is a Niche Signal for Subventricular  
655 Zone Neural Stem Cell Amplification and Self-Renewal. *Stem Cells* **27**, 408-419,  
656 doi:10.1634/stemcells.2008-0226 (2009).
- 657 16 Schetters, S. T. T., Gomez-Nicola, D., Garcia-Vallejo, J. J. & Van Kooyk, Y. Neuroinflammation:  
658 Microglia and T Cells Get Ready to Tango. *Front Immunol* **8**, 1905,  
659 doi:10.3389/fimmu.2017.01905 (2017).
- 660 17 Colonna, M. & Butovsky, O. Microglia Function in the Central Nervous System During Health  
661 and Neurodegeneration. *Annu Rev Immunol* **35**, 441-468, doi:10.1146/annurev-immunol-  
662 051116-052358 (2017).
- 663 18 Caffarel, M. M. & Braza, M. S. Microglia and metastases to the central nervous system:  
664 victim, ravager, or something else? *J Exp Clin Cancer Res* **41**, 327, doi:10.1186/s13046-022-  
665 02535-7 (2022).
- 666 19 Wang, G. *et al.* Tumor-associated microglia and macrophages in glioblastoma: From basic  
667 insights to therapeutic opportunities. *Front Immunol* **13**, 964898,  
668 doi:10.3389/fimmu.2022.964898 (2022).
- 669 20 Blitz, S. E. *et al.* Tumor-Associated Macrophages/Microglia in Glioblastoma Oncolytic  
670 Virotherapy: A Double-Edged Sword. *Int J Mol Sci* **23**, doi:10.3390/ijms23031808 (2022).
- 671 21 Urbantat, R. M. *et al.* Tumor-Associated Microglia/Macrophages as a Predictor for Survival in  
672 Glioblastoma and Temozolomide-Induced Changes in CXCR2 Signaling with New Resistance



673 Overcoming Strategy by Combination Therapy. *Int J Mol Sci* **22**, doi:10.3390/ijms222011180  
674 (2021).

675 22 Andersen, R. S., Anand, A., Harwood, D. S. L. & Kristensen, B. W. Tumor-Associated Microglia  
676 and Macrophages in the Glioblastoma Microenvironment and Their Implications for Therapy.  
677 *Cancers (Basel)* **13**, doi:10.3390/cancers13174255 (2021).

678 23 Radke, J. *et al.* Decoding molecular programs in melanoma brain metastases. *Nature*  
679 *Communications* **13**, 7304, doi:10.1038/s41467-022-34899-x (2022).

680 24 Köhler, C. Allograft inflammatory factor-1/Ionized calcium-binding adapter molecule 1 is  
681 specifically expressed by most subpopulations of macrophages and spermatids in testis. *Cell*  
682 *and Tissue Research* **330**, 291-302, doi:10.1007/s00441-007-0474-7 (2007).

683 25 Yoshihara, K. *et al.* Inferring tumour purity and stromal and immune cell admixture from  
684 expression data. *Nat Commun* **4**, 2612, doi:10.1038/ncomms3612 (2013).

685 26 Ros-Martinez, S., Navas-Carrillo, D., Alonso-Romero, J. L. & Orenes-Pinero, E. Immunoscore: a  
686 novel prognostic tool. Association with clinical outcome, response to treatment and survival  
687 in several malignancies. *Crit Rev Clin Lab Sci* **57**, 432-443,  
688 doi:10.1080/10408363.2020.1729692 (2020).

689 27 Zhang, Y. *et al.* Integrin beta7 Inhibits Colorectal Cancer Pathogenesis via Maintaining  
690 Antitumor Immunity. *Cancer Immunol Res* **9**, 967-980, doi:10.1158/2326-6066.CIR-20-0879  
691 (2021).

692 28 Ge, Q. *et al.* Immunological Role and Prognostic Value of APBB1IP in Pan-Cancer Analysis. *J*  
693 *Cancer* **12**, 595-610, doi:10.7150/jca.50785 (2021).

694 29 Geirsdottir, L. *et al.* Cross-Species Single-Cell Analysis Reveals Divergence of the Primate  
695 Microglia Program. *Cell* **179**, 1609-1622 e1616, doi:10.1016/j.cell.2019.11.010 (2019).

696 30 Lafuente, E. M. *et al.* RIAM, an Ena/VASP and Profilin ligand, interacts with Rap1-GTP and  
697 mediates Rap1-induced adhesion. *Developmental cell* **7**, 585-595,  
698 doi:10.1016/j.devcel.2004.07.021 (2004).

699 31 Inagaki, T. *et al.* The retinoic acid-responsive proline-rich protein is identified in  
700 promyeloleukemic HL-60 cells. *J Biol Chem* **278**, 51685-51692, doi:10.1074/jbc.M308016200  
701 (2003).

702 32 Hoffmann, F. *et al.* Prognostic and predictive value of PD-L2 DNA methylation and mRNA  
703 expression in melanoma. *Clin Epigenetics* **12**, 94, doi:10.1186/s13148-020-00883-9 (2020).

704 33 Chen, S. *et al.* Integrin alphaEbeta7(+) T cells direct intestinal stem cell fate decisions via  
705 adhesion signaling. *Cell research* **31**, 1291-1307, doi:10.1038/s41422-021-00561-2 (2021).

706 34 Zhang, L. *et al.* Single-Cell Analyses Inform Mechanisms of Myeloid-Targeted Therapies in  
707 Colon Cancer. *Cell* **181**, 442-459 e429, doi:10.1016/j.cell.2020.03.048 (2020).

708 35 Schmiedel, B. J. *et al.* Single-cell eQTL analysis of activated T cell subsets reveals activation  
709 and cell type-dependent effects of disease-risk variants. *Sci Immunol* **7**, eabm2508,  
710 doi:10.1126/sciimmunol.abm2508 (2022).

711 36 Weiss, S. A. *et al.* Melanoma brain metastases have lower T-cell content and microvessel  
712 density compared to matched extracranial metastases. *J Neurooncol* **152**, 15-25,  
713 doi:10.1007/s11060-020-03619-0 (2021).

714 37 Griss, J. *et al.* B cells sustain inflammation and predict response to immune checkpoint  
715 blockade in human melanoma. *Nat Commun* **10**, 4186, doi:10.1038/s41467-019-12160-2  
716 (2019).

717 38 Huang, L. *et al.* Correlation of tumor-infiltrating immune cells of melanoma with overall  
718 survival by immunogenomic analysis. *Cancer medicine* **9**, 8444-8456, doi:10.1002/cam4.3466  
719 (2020).

720 39 Saul, D. *et al.* A new gene set identifies senescent cells and predicts senescence-associated  
721 pathways across tissues. *Nat Commun* **13**, 4827, doi:10.1038/s41467-022-32552-1 (2022).

722 40 Pais Ferreira, D. *et al.* Central memory CD8(+) T cells derive from stem-like Tcf7(hi) effector  
723 cells in the absence of cytotoxic differentiation. *Immunity* **53**, 985-1000 e1011,  
724 doi:10.1016/j.immuni.2020.09.005 (2020).

725 41 Sade-Feldman, M. *et al.* Defining T Cell States Associated with Response to Checkpoint  
726 Immunotherapy in Melanoma. *Cell* **176**, 404, doi:10.1016/j.cell.2018.12.034 (2019).

727 42 Connolly, K. A. *et al.* A reservoir of stem-like CD8(+) T cells in the tumor-draining lymph node  
728 preserves the ongoing antitumor immune response. *Sci Immunol* **6**, eabg7836,  
729 doi:10.1126/sciimmunol.abg7836 (2021).

730 43 Fischer, G. M. *et al.* Molecular Profiling Reveals Unique Immune and Metabolic Features of  
731 Melanoma Brain Metastases. *Cancer Discov* **9**, 628-645, doi:10.1158/2159-8290.CD-18-1489  
732 (2019).

733 44 Desole, C. *et al.* HGF and MET: From Brain Development to Neurological Disorders. *Front Cell*  
734 *Dev Biol* **9**, 683609, doi:10.3389/fcell.2021.683609 (2021).

735 45 Zhang, Y. *et al.* Purification and Characterization of Progenitor and Mature Human Astrocytes  
736 Reveals Transcriptional and Functional Differences with Mouse. *Neuron* **89**, 37-53,  
737 doi:10.1016/j.neuron.2015.11.013 (2016).

738 46 Zhang, Y., Jain, R. K. & Zhu, M. Recent Progress and Advances in HGF/MET-Targeted  
739 Therapeutic Agents for Cancer Treatment. *Biomedicines* **3**, 149-181,  
740 doi:10.3390/biomedicines3010149 (2015).

741 47 Ramani, N. S., Morani, A. C. & Zhang, S. MET Gene High Copy Number  
742 (Amplification/Polysomy) Identified in Melanoma for Potential Targeted Therapy. *Am J Clin*  
743 *Pathol* **157**, 502-505, doi:10.1093/ajcp/aqab171 (2022).

744 48 Rozeman, E. A. *et al.* Survival and biomarker analyses from the OpACIN-neo and OpACIN  
745 neoadjuvant immunotherapy trials in stage III melanoma. *Nat Med* **27**, 256-263,  
746 doi:10.1038/s41591-020-01211-7 (2021).

747 49 Reijers, I. L. M. *et al.* The interferon-gamma (IFN- $\gamma$ ) signature from baseline tumor material  
748 predicts pathologic response after neoadjuvant ipilimumab (IPI) + nivolumab (NIVO) in stage  
749 III melanoma. *Journal of Clinical Oncology* **40**, 9539-9539,  
750 doi:10.1200/JCO.2022.40.16\_suppl.9539 (2022).

751 50 Subramanian, A. *et al.* Gene set enrichment analysis: a knowledge-based approach for  
752 interpreting genome-wide expression profiles. *Proc Natl Acad Sci U S A* **102**, 15545-15550,  
753 doi:10.1073/pnas.0506580102 (2005).

754 51 Gonzalez, H. *et al.* Cellular architecture of human brain metastases. *Cell* **185**, 729-745 e720,  
755 doi:10.1016/j.cell.2021.12.043 (2022).

756 52 Dufner, A., Andjelkovic, M., Burgering, B. M., Hemmings, B. A. & Thomas, G. Protein kinase B  
757 localization and activation differentially affect S6 kinase 1 activity and eukaryotic translation  
758 initiation factor 4E-binding protein 1 phosphorylation. *Mol Cell Biol* **19**, 4525-4534,  
759 doi:10.1128/MCB.19.6.4525 (1999).

760 53 Seip, K. *et al.* Fibroblast-induced switching to the mesenchymal-like phenotype and  
761 PI3K/mTOR signaling protects melanoma cells from BRAF inhibitors. *Oncotarget* **7**, 19997-  
762 20015, doi:10.18632/oncotarget.7671 (2016).

763 54 Yan, Y. *et al.* Vemurafenib and Cobimetinib Potently Inhibit Ps6 Signaling in Brafv600  
764 Mutation&#x2013;Positive Locally Advanced or Metastatic Melanoma from Brim7 Study.  
765 *Annals of Oncology* **25**, iv378, doi:10.1093/annonc/mdu344.9 (2014).

766 55 Zhao, S. *et al.* Selective Inhibitor of the c-Met Receptor Tyrosine Kinase in Advanced  
767 Hepatocellular Carcinoma: No Beneficial Effect With the Use of Tivantinib? *Front Immunol*  
768 **12**, 731527, doi:10.3389/fimmu.2021.731527 (2021).

769 56 Quail, D. F. & Joyce, J. A. The Microenvironmental Landscape of Brain Tumors. *Cancer cell* **31**,  
770 326-341, doi:10.1016/j.ccell.2017.02.009 (2017).

771 57 Roesler, R., Dini, S. A. & Isolan, G. R. Neuroinflammation and immunoregulation in  
772 glioblastoma and brain metastases: Recent developments in imaging approaches. *Clin Exp*  
773 *Immunol* **206**, 314-324, doi:10.1111/cei.13668 (2021).

774 58 He, X., Guo, Y., Yu, C., Zhang, H. & Wang, S. Epithelial-mesenchymal transition is the main  
775 way in which glioma-associated microglia/macrophages promote glioma progression. *Front*  
776 *Immunol* **14**, 1097880, doi:10.3389/fimmu.2023.1097880 (2023).

777 59 Zhai, H., Heppner, F. L. & Tsirka, S. E. Microglia/macrophages promote glioma progression.  
778 *Glia* **59**, 472-485, doi:10.1002/glia.21117 (2011).

779 60 Sofroniew, M. V. Astrogliosis. *Cold Spring Harbor perspectives in biology* **7**, a020420,  
780 doi:10.1101/cshperspect.a020420 (2014).

781 61 Herrmann, J. E. *et al.* STAT3 is a critical regulator of astrogliosis and scar formation after  
782 spinal cord injury. *J Neurosci* **28**, 7231-7243, doi:10.1523/JNEUROSCI.1709-08.2008 (2008).

783 62 Priego, N. *et al.* STAT3 labels a subpopulation of reactive astrocytes required for brain  
784 metastasis. *Nat Med* **24**, 1024-1035, doi:10.1038/s41591-018-0044-4 (2018).

785 63 Maina, F., Hilton, M. C., Ponzetto, C., Davies, A. M. & Klein, R. Met receptor signaling is  
786 required for sensory nerve development and HGF promotes axonal growth and survival of  
787 sensory neurons. *Genes Dev* **11**, 3341-3350, doi:10.1101/gad.11.24.3341 (1997).

788 64 Garcia-Diaz, A. *et al.* Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2  
789 Expression. *Cell Rep* **29**, 3766, doi:10.1016/j.celrep.2019.11.113 (2019).

790 65 Verhelst, J., Parthoens, E., Schepens, B., Fiers, W. & Saelens, X. Interferon-inducible protein  
791 Mx1 inhibits influenza virus by interfering with functional viral ribonucleoprotein complex  
792 assembly. *J Virol* **86**, 13445-13455, doi:10.1128/JVI.01682-12 (2012).

793 66 Acker, G. *et al.* The CXCR2/CXCL2 signalling pathway - An alternative therapeutic approach in  
794 high-grade glioma. *Eur J Cancer* **126**, 106-115, doi:10.1016/j.ejca.2019.12.005 (2020).

795 67 Jiang, H., Lei, R., Ding, S. W. & Zhu, S. Skewer: a fast and accurate adapter trimmer for next-  
796 generation sequencing paired-end reads. *BMC Bioinformatics* **15**, 182, doi:10.1186/1471-  
797 2105-15-182 (2014).

798 68 Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for  
799 RNA-seq data with DESeq2. *Genome Biol* **15**, 550, doi:10.1186/s13059-014-0550-8 (2014).

800 69 Mootha, V. K. *et al.* PGC-1alpha-responsive genes involved in oxidative phosphorylation are  
801 coordinately downregulated in human diabetes. *Nat Genet* **34**, 267-273, doi:10.1038/ng1180  
802 (2003).

803 70 Hanzelmann, S., Castelo, R. & Guinney, J. GSVA: gene set variation analysis for microarray  
804 and RNA-seq data. *BMC Bioinformatics* **14**, 7, doi:10.1186/1471-2105-14-7 (2013).

805 71 Biermann, J. *et al.* Dissecting the treatment-naive ecosystem of human melanoma brain  
806 metastasis. *Cell* **185**, 2591-2608 e2530, doi:10.1016/j.cell.2022.06.007 (2022).

807 72 Schildhaus, H. U. *et al.* MET amplification status in therapy-naive adeno- and squamous cell  
808 carcinomas of the lung. *Clin Cancer Res* **21**, 907-915, doi:10.1158/1078-0432.CCR-14-0450  
809 (2015).

810 73 Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using real-time  
811 quantitative PCR and the 2<sup>-Delta Delta C(T)</sup> Method. *Methods* **25**, 402-408,  
812 doi:10.1006/meth.2001.1262 (2001).

813

814

815

816

817

## 818 **Figure legends**

819 **Figure 1: Transcriptome and methylome profiling of Iba1<sup>high</sup> and Iba1<sup>neg</sup> MBM revealed**  
820 **identification of subset-specific genes.** a.) Immunohistochemistry (IHC) for Iba1 (red) of  
821 MBM of indicated patients. b.) Representative IHC for levels of CD3 in Iba1<sup>high</sup> (Pat 4) and  
822 Iba1<sup>neg</sup> (Pat 1) MBM. c.) Immune score of MBM (study EGAS00001005976, n=16) indicating  
823 different immunologic (color coded) subsets of tumors. d.) Dot plot showing the significant  
824 correlation of Iba1/AIF1 expression and immune score of brain metastases (BM, R=0.86,  
825  $p < 2.2 \times 10^{-16}$ ) and extracranial metastases (EM, R=0.78,  $p = 5.5 \times 10^{-13}$ ). e.) Survival analysis of  
826 patients with MBM (study, EGAS00001003672), featuring high or low level of Iba1/AIF1  
827 expression revealed no significant difference ( $p = 0.11$ ). f.) Survival analysis of TCGA  
828 melanoma patients (n=459), featuring high or low level of Iba1/AIF1 expression revealed  
829 significant difference (logrank  $p = 1.3 \times 10^{-7}$ ) and Cox-regression analysis showed association  
830 with favorable disease course (HR=0.46). g.) Schematic representation of candidate  
831 identification by methylome and transcriptome profiling of n=16 MBM of study. Methylome  
832 (850k) profiling of Iba1<sup>high</sup> (n=5) or Iba1<sup>neg</sup> (n=2) identified 416 differentially methylated  
833 regions (DMRs), within the 5'-UTR of 316 corresponding genes of which 296 were  
834 expressed in MBM with 56 genes (77 DMRs), significantly ( $p \leq 0.05$ ) discriminating Iba1<sup>high</sup>  
835 and Iba1<sup>low/neg</sup> MBM. h.) Heat map representation of 77 DMRs (left panel) and top expressed  
836 (right panel) genes (n=31). Analysis identified a panel of 12 genes that clustered with  
837 expression of microglia/TAM-associated genes AIF1, SYK and HCK. i.) Correlation analysis  
838 of cluster genes with association to immune/TAM regulated processes, strength of  
839 correlation is color coded. j.) Comparative t-SNE representation of brain cell subclasses  
840 microglia, neurons and oligodendrocytes (left) and expression of *APBB1IP* (Amyloid Beta  
841 Precursor Protein Binding Family B Member 1 Interacting Protein), expression level (log2  
842 RPKM) is color coded. k.) Dot plot showing the significant correlation of *APBB1IP* expression  
843 and immune score of brain metastases (BM, R=0.86,  $p < 2.2 \times 10^{-16}$ ) and extracranial

844 metastases (EM,  $R=0.92$ ,  $p<2.2e-16$ ). Significance was determined by unpaired, two-sided t-  
845 test (d, g, k).

846 **Figure 2: Expression of ITGB7 serves as indicator of lymphocyte infiltration.** a.) Box  
847 plot representation of levels of ITGB7 indicates a wide pattern of expression among indicated  
848 immune cell populations. Monocytes and neutrophil granulocytes show low levels of ITGB7.  
849 b.) IHC of a representative MBM of a patient with refractory intracranial disease for Iba1 (red,  
850 first column) and CD3 (brown, second column) indicating focal enrichment of  
851 microglia/macrophages and CD3<sup>+</sup> T cells within ITGB7 positive areas (red, second column).  
852 Hematoxylin and eosin (H&E) staining shows discrimination of tumor cells and tumor-  
853 infiltrating lymphocytes (TILs) c.) Expression (FPKM, log2) of CD4, PD-L1 (CD274) and  
854 SUSD3 in MBM with high or low level of ITGB7, indicating cellular co-occurrence. d.) Dot plot  
855 showing the significant inverse correlation ( $R=-0.87$ ,  $p=5.2e-05$ ) of  $\beta$ -values (probe  
856 cg26689077) indicating the methylation level at a site located within the proximal enhancer-  
857 like structure of the ITGB7 gene and immune score of MBM (n=14) of study  
858 EGAS00001005976 (first panel). Box plots represent a significant ( $p=4.5e-04$ ) or non-  
859 significant ( $p=0.86$ ) association of ITGB7 methylation (probe cg26689077) or BRAF mutation  
860 status (center and right panels) of all MBM investigated (n=21). e.) Dot plot showing the  
861 significant correlation of ITGB7 expression and immune score of MBM ( $R=0.51$ ,  $p=1.8e-06$ )  
862 and EM ( $R=0.61$ ,  $p=1.1e-09$ ) indicating immune-related expression of ITGB7 irrespective of  
863 the side of metastasis. f.) Correlation map showing high association ( $p<0.05$ ) of ITGB7 with  
864 relevant immune cell markers such as PD-1 (PDCD1), PD-L1 (CD274), PD-L2 (PDCD1LG2)  
865 but low correlation with tumor cell markers NGFR, MITF, MLANA or SLC45A2. g.) Dot plot  
866 showing the significant correlation of ITGB7 and expression of PD-L2 (BM:  $R=0.45$ ,  $p=3.4e-$   
867  $05$ ; EM:  $R=0.42$ ,  $p=1.1e-03$ ) and SUSD3 (BM:  $R=0.44$ ,  $p=5.2e-05$ ; EM:  $R=0.61$ ,  $p=2.6e-07$ ).  
868 h.) Dot plot showing the correlation of ITGB7 expression and immune score of primary (PT;  
869  $R=0.59$ ,  $p=9.4e-16$ ), metastatic (EM;  $R=0.78$ ,  $p=2.2e-16$ ) and brain metastatic (BM;  $R=0.2$ ,  
870  $p=0.61$ ) melanoma (TCGA-SKCM), indicating that expression of ITGB7 is independent from  
871 melanoma progression stages. i.) Survival analysis of TCGA melanoma patients (n=459),

872 featuring high or low level of ITGB7 and SUSD3 expression revealed significant difference  
873 (logrank  $p=4.0e-04$  and  $p=6.6e-08$ ) and Cox-regression analysis showed association with  
874 favorable disease course (HR=0.60 and HR=0.48). Box and whisker plots show median  
875 (center line), the upper and lower quartiles (the box), and the range of the data (the  
876 whiskers), including outliers (a, c, d). Significance was determined by unpaired, two-sided t-  
877 test (c, d) or one-way ANOVA (a).

878 **Figure 3: Signature-based deconvolution identified parameter of MBM featuring a**  
879 **favorable disease course and identified a role of MET signaling.** a.) Single-sample  
880 GSEA (ssGSEA)-based deconvolution of MBM of study EGAS00001005976 using  
881 customized gene signatures indicating “Signaling” processes, cellular subsets and stages of  
882 microglia and astrocyte and immune cell subsets. ssGSEA demonstrated distinct separation  
883 of MBM with high, median or low immune score regarding expression levels of signature  
884 genes, BMCs served as controls. ssGSEA uncovered differentially activated pathways and  
885 processes such as MET and STAT3 and interferon signaling, senescence (SenMayo), stress  
886 response and tumor inflammation in tumors enriched for reactive microglia and astrocytes  
887 and innate and acquired immune cells subsets. b.) Confocal microscopy images of orthotopic  
888 tumors established by stereotactic injection of BMC1-M4 or BMC2 cells into brains of  
889 Crl:CD1-Foxn1<sup>nu</sup> mice<sup>23</sup>, stained for Iba1 (green, microglia) or Iba1, GFAP (red, astrocytes)  
890 and KBA.62 (turquoise, pan-melanoma cell marker). DAPI served as nuclear dye. Markers  
891 show distinct areas of tumor (MBM) and microenvironment (TME) and regions of microglia  
892 infiltration, 21 days after intracranial injection<sup>23</sup>. MBM-TME borders are indicated by white,  
893 dashed lines. c.) IHC of tumors investigated in (a) for activation and tyrosine phosphorylation  
894 (residue Y705) of STAT3. pSTAT3<sup>Y705</sup> is particularly present in microenvironmental cells  
895 (astrocytes). Black, dashed lines indicate MBM-TME borders. In b, c, bars indicate 50  $\mu$ m.  
896 d-e.) Expression levels of hepatocyte growth factor (HGF) in tumors of studies  
897 EGAS00001005976, TCGA-SKCM and EGAS00001003672 demonstrating HGF expression  
898 in all tumor subsets. f-g.) Investigation of HGF expression in immune cell subsets (DICE  
899 database<sup>35</sup>) and brain cells (study GSE73721) revealed highest levels in basophil

900 granulocytes and monocytes (f) and in astrocytes and microglia (g). h.) UMAP projection of  
901 expression profiles from nuclei isolated from 5 neurotypical donors as provided by Seattle  
902 Alzheimer's disease brain cell atlas ([https://portal.brain-map.org/explore/seattle-alzheimers-](https://portal.brain-map.org/explore/seattle-alzheimers-disease)  
903 [disease](https://portal.brain-map.org/explore/seattle-alzheimers-disease)), cellular subtypes are color coded (left panel). Log-normalized expression levels of  
904 HGF in nuclei isolated from 5 neurotypical donors (center panel). Log-normalized expression  
905 levels of HGF in nuclei isolated from 84 aged donors (42 cognitively normal and 42 with  
906 dementia), right panel, demonstrating increased number of HGF expressing microglia and  
907 astrocytes as triggered by inflammatory processes. i.) Dot plot showing the correlation of  
908 HGF expression and immune score of BM ( $R=0.49$ ,  $p=5.3e-06$ ) and EM ( $R=0.41$ ,  $p=1.5e-03$ )  
909 indicating a potential role of HGF in immune cell-related processes. Box and whisker plots  
910 show median (center line), the upper and lower quartiles (the box), and the range of the data  
911 (the whiskers), including outliers (d-g). Significance was determined by unpaired, two-sided t-  
912 test (e) or one-way ANOVA (g).

913 **Figure 4: Ecad<sup>+</sup> MBM are defined by expression of MET receptor.** a.) Schematic  
914 summary of the initial screen of MBM expression data of our recent study  
915 (EGAS00001005976; n=16 MBM) for subset expressed receptors. MBM contain Ecad<sup>+</sup> and  
916 NGFR<sup>+</sup> subsets and admixed cells such reactive microglia, labeled by expression of  
917 Iba1/AIF1 and or P2RY12. The initial survey yielded 24 receptors that potentially establish  
918 cell survival/growth of MBM. b.) Correlation map (Spearman,  $p<0.05$ ) showing the  
919 relationship of identified receptors expressed in MBM of our previous study, emphasizing the  
920 distinct pattern of Ecad<sup>+</sup> and NGFR<sup>+</sup> molecular subsets. The value of the correlation  
921 coefficient is color coded. c.) Box plots depicting the levels of most relevant receptors that  
922 significantly separated Ecad<sup>high</sup> and Ecad<sup>low</sup> subsets of MBM and extracerebral metastases  
923 (EM) of study EGAS00001003672, providing MBM = 79, EM = 59 (ADIPOR1, Adiponectin  
924 Receptor 1,  $p=0.019/7.9e-05$ ; SIRPA, Signal Regulatory Protein Alpha,  $p=1.1e-05/0.0046$ ;  
925 PLXNC1, Plexin C1,  $p=4.6e-06/3e-04$ ). d.) Box plots depicting the levels of MET in Ecad<sup>high</sup>  
926 and Ecad<sup>low</sup> subsets of MBM and EM (left panel,  $p=1.4e-04/p=0.41$ ) or in all subtypes of  
927 MBM and EM ( $p=2.7e-05$ ) in high and low proliferating tumor cell subsets (right panel,

928  $p=9.1e-03$ ). e.) IHC of selected MBM for MET and MITF validated the two subsets. f-g.)  
929 Expression and activation status of MET in BRAF wildtype (wt; Pts 14, 39) and BRAF<sup>V600E/R</sup>  
930 mutated MBM (Pts 28, 29, 31). Phosphorylation of MET at residues Y1234/1235 is critical for  
931 kinase activation. h.) IHC of indicated tumors for co-localization of pMET<sup>Y1234/1235</sup> (brown) and  
932 Iba1 (red) demonstrating potential activation of MET receptor signaling tumor cells by stromal  
933 cell-secreted HGF. i.) Heat map representing expression levels of regulators and targets of  
934 interferon signaling and immune related genes showing clustering according to the level of  
935 ITGB7 expression. Box and whisker plots show median (center line), the upper and lower  
936 quartiles (the box), and the range of the data (the whiskers), including outliers (c, d).  
937 Significance was determined by unpaired, two-sided t-test (c, d).

938 **Figure 5: Inhibitors of MET receptor decrease growth of brain metastatic and**  
939 **conventional melanoma cell lines.** a.) Comparative IHC of selected MBM for levels of  
940 phosphorylated and activated MET receptor (pMET<sup>Y1234/1235</sup>) and ribosomal protein S6  
941 (pS6<sup>235/236</sup>) of consecutive sections suggesting MET-associated activation of mTOR  
942 signaling. b.) Immunofluorescence microscopy of lymph node-metastatic (T2002) and brain  
943 metastatic (BMC53) patient-derived melanoma cell lines for co-occurrence of MET (red) and  
944 pS6<sup>235/236</sup> (green). DAPI served as nuclear dye. c.) qPCR analysis of BMCs for expression of  
945 MET receptor, bars indicate median levels  $\pm$ SD of three biological replicates. d.) Gross initial  
946 ARQ197 sensitivity test of BMC53 and BMC1-M1 cells showing high and low levels of MET  
947 expression. Cell density was determined by crystal violet staining. e.) Broad range  
948 determination of sensitivity of BMCs, T2002 and conventional melanoma cell lines (A375,  
949 A2058, MeWo) to METi PHA-665752 and ARQ197. Cell density and BRAF mutation status  
950 are indicated. Dotted line depicts the estimated range of IC<sub>50</sub>. f.) PHA-665752 dose-response  
951 fit curve-based calculation of IC<sub>50</sub> values of A375 cells with overexpression of NGFR or RFP  
952 control cells and MeWo cells. g.) Dabrafenib dose-response fit curve-based calculation of  
953 IC<sub>50</sub> values of BMCs exhibiting different BRAF mutations (BMC2<sup>p.N581Y</sup>, BMC4<sup>p.V600K</sup>) and  
954 A375<sup>p.V600E</sup>, A2058<sup>p.V600E</sup> cells. h-i.) Live cell imaging-based tracking of confluence (%) of  
955 BMC2 and BMC4 cells in dependence of increasing doses of ARQ197. Shown are median



956 values±SD of eight technical replicates. A representative out of two experiments is shown. j.)  
957 ARQ197 dose-response fit curves of BMCs, T2002 and conventional cell lines. Calculated  
958 IC<sub>50</sub> values are indicated, suggesting response of dabrafenib resistant cell lines to METi. k.)  
959 Bar diagram summarizing IC<sub>50</sub> values (nM) indicating the response of indicated cell lines to  
960 ARQ197. The BRAF status is color coded. l.) Working model suggesting the activation of  
961 MET receptor signaling in adjacent tumor cells and in (reactive) microglia (RM) by microglia  
962 released HGF. IRF-mediated HGF expression in turn is triggered by immune cell  
963 (monocytes/macrophages, M) released interferon-gamma. HGF binding to tumor cell (TC)  
964 expressed MET receptor directs downstream activation of the RAS/RAF/MEK/ERK and the  
965 PI3K/AKT/mTOR/p70S6K branch. The latter is leading to phosphorylation and activation of  
966 the ribosomal protein S6. Box and whisker plots show median (center line), the upper and  
967 lower quartiles (the box), and the range of the data (the whiskers), including outliers (c).

968 **Figure 6: HGF/MET receptor signaling might be activated in tumor cells at immune**  
969 **cell/TAM dense areas.** Schematic representation of our working model suggesting the  
970 interaction of tumor cells with stromal cells, particularly microglia and immune cells,  
971 consequentially leading to activation of MET signaling in tumor cells via stromal cell-released  
972 HGF. Expression of HGF in turn and ITGB7 and PD-L1 is likely triggered by T cell provided  
973 interferon-gamma. Increased levels of ITGB7 may foster recruitment of immune cells.

974

975

976

977

978

979

980

981 **Supplementary figure legends**

982 **Supplementary figure 1: Iba1/AIF1 expression separates MBM** a.) Immunofluorescence  
983 (IF) for Iba1 (red) and GFAP (labeling of reactive and normal astrocytes) of a *NRAS*<sup>Q61R</sup>  
984 mutated MBM (Pat 15) that progressed on treatment with immune checkpoint inhibitors (ICi;  
985 ipilimumab) showed strong infiltration of tumor-associated microglia/macrophages (TAMs)  
986 and the presence of aggregates of microglia and reactive astrocytes. MBM (without adjacent  
987 stromal cells) of Pat 3 showed high infiltration of TAMs. DAPI served as nuclear dye. b.) Box  
988 plots representing the levels (FPKM, log2) of Iba1/AIF1 in MBM and BMC of study  
989 EGAS00001005976 and MBM and EM of study EGAS00001003672. c.) Per sample  
990 representation of expression levels (FPKM, log2) of Iba1/AIF1 in MBM, brain metastases-  
991 derived cell lines (BMCs) and brain controls (BC) of studies mentioned in (b). d-f.) Survival  
992 analyses of MBM patients (n=67) of study EGAS00001003672 or of TCGA-SKCM study  
993 (n=459), featuring high or low level of *APBB1IP* (d, e) or PD-L2 (*PDCD1LG2*) expression.  
994 Analysis revealed a significant (logrank  $p=5.5e-07$ ) favorable disease course (HR=0.50, Cox-  
995 regression analysis) of *APBB1IP*<sup>high</sup> melanoma (e) and favorable outcome associated with  
996 high levels of PD-L2 expression in MBM (f). Survival of MBM patients was not significantly  
997 affected by *APBB1IP* levels (d). g.-m.) Correlation and cell type-specificity of microglia  
998 markers *SYK*, *HCK*, *P2RY12* and *AIF1*. n.) Dot plot shows significant ( $R=0.85$ ,  $p=1.3e-04$ )  
999 correlation of *ITGB7* expression of MBM (n=16, study EGAS00001005976) and immune  
1000 score. Box and whisker plots show median (center line), the upper and lower quartiles (the  
1001 box), and the range of the data (the whiskers), including outliers (b).

1002

1003 **Supplementary figure 2: The indicators of favorable disease course *ITGB7*, *SUSD3* and**  
1004 ***APBB1IP* are broadly expressed among immune cell subsets.** a.) Box plots showing  
1005 expression levels of *ITGB7* among T cell subsets (CD4, T helper cells), CD8 (cytotoxic T  
1006 cells), NK cells (natural killer cells), cDC (conventional dendritic cells), pDC (plasmacytoid  
1007 dendritic cells) lymphoid follicle-residing B cells (FollicularB cell subsets), innate lymphoid

1008 cells, type 3 (ILC3), mast cells, macrophages (Macro), monocyte subsets (Mono), myofibrils  
1009 (non-immune related cells), plasma cells (PlasmaB) and tumor-associated macrophages  
1010 (TAMs) as provided by study GSE146771. b.) IHC of MBM of indicated patients for ITGB7.  
1011 ITGB7 expression is evident in lymphocyte-enriched areas. c.-d.) Boxplot showing  
1012 expression levels of SUSD3 in immune cell subsets of (a), and shows levels obtained from  
1013 DICE (Database of Immune Cell Expression, Expression quantitative trait loci (eQTLs) and  
1014 Epigenomics), suggesting broad but variable expression among immune cell subsets. e.)  
1015 Comparative illustration of levels of ITGB7 and SUSD3 as requested from DICE. f.) Box plot  
1016 showing expression levels of APBB1IP among immune cell subsets of the aforementioned  
1017 GEO study, suggesting a broad expression among immune cell types. Box and whisker plots  
1018 show median (center line), the upper and lower quartiles (the box), and the range of the data  
1019 (the whiskers), including outliers (a, c, d, f).

1020

1021 **Supplementary figure 3: Methylome profiling uncovered epigenetic regulatory sites in**  
1022 **the ITGB7 gene.** a.) Schematic representation of the ITGB7 gene, showing exons, intronic  
1023 regions and sites of epigenetic marks as depicted by indicated probes. ITGB7 expression  
1024 levels are associated with methylation at sites covered by probes cg26689077 and  
1025 cg01033299 located within a proximal enhancer-like signature and intronic region close to 5'-  
1026 UTR. Additional regions as covered by probes cg18320160 and cg11510999 are associated  
1027 with the BRAF mutation status of tumors. b.-c.) Dot plots showing no significant correlation  
1028 of methylation status (indicated by  $\beta$ -values) at sites covered by probes cg18320160 and  
1029 cg11510999 and immune score. d.-e.) Box pots indicating a significant association of  $\beta$ -  
1030 values, determined by aforementioned probes (cg11510999,  $p = 3e-06$ ; cg18320160,  $p =$   
1031  $0.003$ ) and BRAF status (BRAF<sup>V600</sup> vs. wt/NRAS<sup>Q61</sup>) of MBM. Box and whisker plots show  
1032 median (center line), the upper and lower quartiles (the box), and the range of the  
1033 data (the whiskers), including outliers (d, e).

1034

1035 **Supplementary figure 4: Single sample GSEA revealed classification of immune**  
1036 **molecular subtypes of MBM.** a.) Single-sample GSEA (ssGSEA)-based deconvolution of  
1037 MBM (n=79) of study EGAS00001003672 using customized gene signatures indicating  
1038 “Signaling” processes, cellular subsets and stages of microglia and astrocyte and immune  
1039 cell subsets. ssGSEA demonstrated distinct separation of MBM with high, median or low  
1040 immunescore regarding expression levels of signature genes, BMCs served as controls.  
1041 ssGSEA uncovered differentially activated pathways and processes such as MET and  
1042 STAT3 and interferon signaling, senescence (SenMayo), stress response and tumor  
1043 inflammation in tumors enriched for reactive microglia and astrocytes and innate and  
1044 acquired immune cells subsets. b.) Boxplot showing expression levels of HGF in indicated  
1045 immune cell subsets obtained from DICE. c.-e.) Expression of MET receptor pathway genes  
1046 in MBM of study EGAS00001003672 showing high or low enrichment of microglia, as  
1047 determined by levels of microglia-specific genes (SYK, HCK, AIF1/Iba1= microglia score  
1048 suggests a significant correlation of microglia infiltration and activation of MET receptor  
1049 signaling. HGF, hepatocyte growth factor ( $p=1.8e-09$ ); PIK3CG, Phosphatidylinositol-4,5-  
1050 Bisphosphate 3-Kinase Catalytic Subunit Gamma ( $p<2.2e-16$ ); PTK2B, Protein Tyrosine  
1051 Kinase 2 Beta ( $p<2.2e-16$ ); STAT3, Signal Transducer And Activator Of Transcription 3  
1052 ( $p=5.3e-11$ ); MAP4K1; Mitogen-Activated Protein Kinase Kinase Kinase Kinase 1 ( $p=3.4e-$   
1053  $12$ ). Box and whisker plots show median (center line), the upper and lower quartiles (the  
1054 box), and the range of the data (the whiskers), including outliers (b-e).

1055 **Supplementary figure 5: MET-FISH analysis revealed absence of MET receptor**  
1056 **amplifications in MBM.** a.) Hematoxylin and eosin (H&E) staining shows tumor cell  
1057 histology (upper row). Fluorescence in-situ hybridization with a MET-specific probe (red)  
1058 revealed no specific amplifications of the MET gene in MBM (n=7) as compared with  
1059 centromere control (green) and irrespective of the BRAF/NRAS mutation status. DAPI served  
1060 as nuclear dye, bars indicate 50  $\mu$ m. b.) Quantitative representation of FISH analysis,  
1061 indicating the number of MET copies per nucleus and ratio of MET and CEP7 (Centromer 7).  
1062 c.) IHC for Iba1 (red) and pMET<sup>Y1234/1235</sup> (brown) revealed absence of activated MET in

1063 Iba1<sup>high</sup> microglia residing in adjacent tissue (upper panel) and MET activation in tumor cells  
1064 without neighboring TAMs. d.) HGF expression in brain cells residing within the different  
1065 lobes (FL, frontal; PL, parietal; TL, temporal; OL, occipital lobe) and pons as retrieved from  
1066 the Allan Brain Atlas (<https://portal.brain-map.org/>). Box and whisker plots show median  
1067 (center line), the upper and lower quartiles (the box), and the range of the data (the  
1068 whiskers), including outliers (d).

1069


1070 **Supplementary figure 6: Expression of interferon-related genes is enriched in MBM of**

1071 **ITGB7<sup>high</sup>/IScore<sup>high</sup> phenotype.** a.) Heat map indicating expression levels and subset-  
1072 association of interferon-inducible genes, mediators of interferon signaling and relevant  
1073 immune cell-expressed markers such as CD3E, CD4, CD8A in MBM (n=79) of study  
1074 EGAS00001003672. Molecular subsets, category of genes and strength of expression are  
1075 color coded. b.-d.) Dot plots indicating the significant correlation of *ITGB7*, *IRF1* (Interferon  
1076 Regulatory Factor 1), *IRF8* and *IFNG* in MBM and EM of the aforementioned study. e.) Dot  
1077 plots indicating the significant correlation of expression of *HGF*, *IRF1* and *IRF8* in MBM and  
1078 EM of the aforementioned study. f.-g.) Investigation of expression data of murine BV2  
1079 microglia cells (study GSE132739) following interferon (1 U/mL IFN $\gamma$ , 24h) or control  
1080 treatment revealed interferon-responsible genes. Interferon treatment significantly increased  
1081 levels of *Itgb7* (p=2.9e-03), *Hgf* (p=4.4e-02), *Mx1* (p=1.2e-02), *Cd274* (p=3.6e-02), *Irf1*  
1082 (p=3.1e-02), *Cxcl9* (p=4.0e-03) and *Aif1* (p=4.0e-03). However, *Susd3* was significantly  
1083 downregulated upon interferon treatment (p=4.0e-02). h.) ssGSEA analysis of MBM with  
1084 defined signatures showing enrichment of interferon-related signaling among other indicated  
1085 processes. Box and whisker plots show median (center line), the upper and lower quartiles  
1086 (the box), and the range of the data (the whiskers), including outliers (f, g).


1087

1088 **Supplementary figure 7: The mTOR/pS6 signaling is activated in MBM.** a.) IHC of MBM  
1089 (Pat 14) for levels of activated/phosphorylated MET receptor (pMET<sup>Y1234/1235</sup>) and mTOR/pS6  
1090 (pS6<sup>S235/236</sup>) signaling revealed co-occurrence of both. b.) Co-occurrence of pS6<sup>S235/236</sup> and




1091 MITF. Bars indicate 50  $\mu\text{m}$ . c.) Confocal microscopy imaging of BMC1-M1 and BMC53 cells  
1092 for levels of NGFR and MET showing a mutually exclusive expression pattern or low level of  
1093 MET in NGFR<sup>+</sup> cells. d.) Live cell imaging tracked dose-response of BMC1-M1 cells to  
1094 increasing doses of ARQ197.












Redmer et al., Figure 3







# Interferon-induced HGF stimulates MET signaling in MBM

